Neurotrophins and their receptors are attracting increasing attention as therapeutic targets in many cancer types, as pharmacological interventions against this signaling axis have the potential to not only target cancer cells directly, but also to inhibit neurogenesis and its stimulatory effects on cancer progression and pain [73,84]. This evidence concerns the gene BDNF and cancer.